First, some HER2 imaging agents have been studied in clinic, including 89Zr-trastuzumab [42] and 68 Ga-HER2 affinity [43],18F-nanobody [44] etc. However, which are not mature and still in the stage to evaluate whether tumor uptake of HER2 imaging can distinguish HER2-positive from HER2-negative breast cancer. Here, ERBB2 is linked to breast carcinoma.